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Ketamine kinetics in unmedicated and diazepam- 
prernedicated subjects 
Plasma ketamine concentrutions after diazepam and placebo pretreatment were examined in a 
double-blind, randomized, cross-otvr study. Eight healthy male subjects received either 
diazepam or u 0.9% NaCl placebo before ketarnine and received the alternate combination 5 to 
24 days later. Ten minutes before ketamine dosing, diazepam, 0.3 mgikg, or placebo in equal 
volume was injected intravenously at a rate not exceeding .S rtrg/nzin. Ketumine, 2.2 mglkg iv, 
was injected over / min. For the clinically relevant period for unesthtsiu ( I  to 30 min), 
diazepum-ketumine treatnmt resulted in higher plasm~l levels at most time points, but diazepam 
pretreatment did not alter plasmu levels of metabolite KI and pseudometabolite KII nor the 
24-hr urinan excretion of ketarnine, Kl,  and KII. Ketamine kinetics followed a three-term 
exponential dodine under both treatment conditions. After placebo-ketamine dosing, plasma 
t%s MVI-e cis ~bl lows:  distribution (rrr%) = 24.1 sec, redistribution ( a t % )  = 4.68 min, and 
rlirninutiort ( p i % )  = 2.17 hr. After cliuzep~lm-kettm~irle dosing, t%s were: 71.1% = 25.0 sec, 
a t% = 6.37 rnin, and P I %  = 17.32 hr. 
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It has been shown that, when injected intrave- 
nously just before ketamine dosing, benzodi- 
azepines such as diazepam markedly improve 
the course of anesthe~ia.~-"' The diazepam- 
ketamine combination has been' reported to in- 
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crease patient acceptance4. l7 and to induce 
less cardiovascular stimulation than ketamine 
anesthesia without diazepam pretreatment. We 
compared ketamine kinetics after placebo and 
diazepam premedication. A report of a two- 
compartment open model analysis of ketamine 
kinetics from 5 min to 24 hr after dosing re- 
vealed that ketamine plasma clearance was re- 
duced by diazepam premedicati~n,~,  and 
plasma ketamine kinetics are triexponential in 
hospitalized surgical patients." These findings 
prompted a more detailed kinetic analysis of 
ketamine. 
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Table I. Analysis of vuriunce for ketamine plasma levels ( t~giml)  
Time cqter 1 Plncebo I Diuzepom ketuminr dosing ( N  = 8)  (N = 7 )  
I rnin 
2 min 
3 min 
4 min 
5 min 
10 min 
2 0  min 
30 min 
I hr 
2 hr 
4 h r  
5 hr 
6 hr 
8 hr 
12 hr 
24 hr 
Data are X % SE 
Table 11. Analysis of variance ,for metabolite Kt plasma /eveis (ngirnl) 
5 rnin 
10 min 
20 min 
30  min 
1 hr 
2 hr 
4 hr 
5 hr 
6 hr 
8 hr 
12 hr 
24 hr 
Time after 
ketczmine dosing 
- 
Data are X i SE. 
Methods 
Placebo 
(N  = 8)  
A double-blind, randomized, crossover de- 
sign was used. Our subjects were eight healthy 
men aged 26 to 41 yr (2 =32.3 yr) weighing 
59.9 to 81.8 kg (% =72.8 kg) who were selected 
from 24 inmates at the Jackson State Prison of 
Southern Michigan. Subjects fasted the night 
before medication. Each received either diaze- 
pam or a 0.9% NaCl placebo before ketamine 
and received the alternate combination 5 to 24 
days later. By chance, the one subject tested at a 
5-day interval received placebo-ketamine first. 
Ten minutes before ketamine dosing, diazepam, 
0 .3  mglkg, or placebo in equal volume was 
injected intravenously at a rate not exceeding 5 
mglmin. Ketamine, 2 .2  mglkg iv, was injected 
over 1 min. One of the subjects (No. 4) refused 
to complete the second portion of the study; 
thus symmetric data are available on only seven 
subjects, and data from subject No. 4 were not 
used in any paired comparisons. Venous injec- 
tions were made in a convenient vein in one arm 
Diuzeprim 
(N = 7 )  
-- - 
P 
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Table 111. Analysis of variance for pseudometabolite KII plasma levels (nglml) 
- 
Data are X 2 SE. 
*Insufficient data after 5 hr with which to do meaningful analysis of variance 
Time after 
ketamine dosing 
Table IV. Ketamine kinetics for a three-compartment open model 
I I 
n t% sec 
at% min 
pt% hr 
k,,*(hr-I) 
k,,*(hr-I) 
k,,*(hr- '1 
k,,*(hr-') 
k,,*(hr- I) 
Vd,? (//kg) 
Vdzt  (1 /kg) 
Vd;,? (1 /kg) 
Vd,,t (llkg) 
Plasma clearance 
(1 Ikglhr) 
10 min 9.10 ? 9.71 38.5 t 32.7 NS 
20 min 50.9 t 43.8 88.5 5 60.2 NS 
30 min 37.9 t 17.0 45.2 t 36.1 NS 
1 hr  91.9 + 45.0 99.1 * 55.3 NS 
2 hr 95.7 t 18.4 151 t 114.3 NS 
4 hr 103 t 14.9 70.8 t 29.8 NS 
5 hr 118 ? 18.3 67.9 * 14.4 * 
6 hr 48.2 t 9.1 1 33.7 t 9.43 * 
8 hr 61.0 t 23.2 58.0 t 10.7 * 
12 hr 47.4 ? 13.4 9.30 t 3.80 * 
24 hr 26.1 t 14.5 0.00 ? 0.00 * 
Placebo 
(N = 8) 
- 
Data are X t SD. Values In parentheses are harmonic means. All kinetic parameters were calculated from the coefficients and exponents 
of the least-squares repression analysis of the data in Table I. 
*Rrst-order rate parameters. 
tVolume of distribution parameters. 
$P < 0.08 (two-tailed paired comparison Student t test); P < 0.05 (one-tailed rest). 
and venous samples were drawn from the other 
arm. The radial artery was used for arterial 
blood pressure recordings and blood sample col- 
lections. Times of sampling are listed in Tables 
I, 11, and 111. All samples were assayed in du- 
plicate. The deviation from scheduled sample 
time was less than 5 to 10 sec. 
The analysis of ketamine and some of its 
metabolites (ketamine metabolite I [KI] and 
ketamine pseudometabolite I1 [KII]) in arterial 
Diazepam 
(N = 7) 
and venous plasma and urine was by gas 
chromatography-mass fragmentography . " Hep- 
tafluorobutyric anhydride derivatives of ket- 
amine, its two metabolites, and the internal 
standard (the o-BR analog of ketamine) were 
prepared after extraction. It should be noted that 
KII does not exist in vivo and is an in vitro 
chemical decomposition product of hydroxyl- 
ated ketamine  metabolite^.'^ Although KII is an 
in vitro decomposition product, it does repre- 
P 
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Fig. 1. Plasma ketamine concentrations in nonsurgi- 
cal subject No. 1 af tg diazepam or placebo pretreat- 
ment. Table I lists X It SE values for all subjects. 
Two separate three-term exponential equations were 
fit by weighted nonlinear least-squares analysis 
(weighed 1 /C2) to diazepam-ketamine (dashed line) 
and placebo-ketamine (solid line) data. 
- 
x 1 
0 200 400 600 800 1000 1200 1100 
Plasma Kctanlnc Clcarancc lml/kg/hrl 
Fig. 2. Relation of plasma ketamine clearance to 
sleep time under diazepam-ketamine and placebo- 
ketamine anesthesia. Analysis of covariance of the 
two treatments revealed an overall correlation of in- 
verse sleep time and plasma clearance (P < 0.01). 
When broken into groups, placebo-ketamine treat- 
ment (o) revealed a correlation (P < 0.05), while 
diazepam-ketamine treatment (a) did not. Mean sleep 
time was elevated in the diazepam-pretreated group 
(P < 0.05). There was no alteration in slopes of the 
regression lines, but there was a trend toward an ad- 
ditive effect of diazepam on duration of anesthesia 
independent of alterations in clearance (P = 0.092). 
An analysis of covariance is summarized in Table V. 
sent at least two in vivo hydroxylated metabo- 
lites. Therefore, data on this decomposition 
product are included in this report as an index of 
these compounds. 
Quantitative analyses were by a Finnigan 
Compartment 2 
--... 
---.. 
L 
; I 
a" 0.1 
0 5 10 15 20 25 30 
Time lminl 
0 5 10 15 20 25 30 
Time Iminl  
Fig. 3. Comparison of compartmental amounts of 
ketamine after diazepam or placebo pretreatment in 
subject No. 7. The time course of the amounts in each 
compartment of a three-compartment model were cal- 
culated from the model obtained from plasma levels 
after diazepam-ketamine (dashed lines) and placebo- 
ketarnine (solid lines) in Subject No. 7. In compart- 
ments one and two, ketamine amounts were slightly 
elevated, while in compartment three, amounts were 
slightly diminished under the diazepam-ketamine 
treatment. Elimination was unchanged between each 
condition. Note the parallel decline of levels in com- 
partments one and two from 5 to 10 min onward. A 
similar model applies for mean data of all subjects. 
3200 GCMS system operated in the electron 
impact mode. A 5 ft x 2 mm glass U-tube col- 
umn packed with 3% OV-17 on 1001 120 mesh 
Gas-Chrom Q was conditioned by heating over- 
night at 250". Chromatographic conditions were 
a column temperature of 180" isothermal and an 
injector temperature of 210". Carrier gas (He) 
flow was 20 ml/rnin, glass jet separator tempera- 
ture was 210°, and electron energy was 70 eV. 
A polyexponential weighted least-squares 
regression analysis was performed by the com- 
puter program NONLIN12 with initial estimates 
from CSTRIP.l"he regression analysis was 
weighted by the inverse of the squared concen- 
tration of ketamine (1/C2). Kinetics were calcu- 
lated from the coefficients and exponents of 
the least-squares regression according to the 
method of Wagner.I5 The optimal number of 
exponential terms for a polyexponential fit 
was obtained by the F test.3 Compartmental 
amounts were calculated by the method of 
Benet.' Statistical calculations, including two- 
way analysis of variance and one-way analysis 
of covariance, were by the Michigan Interactive 
Vollrme 36 
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Table V .  One-way analysis of covariance 
A. Analysis of variance of llsleep time (N = 14); covariate plasma clearance,* treatments = 
Diazepam-ketamine and placebo-ketamine 
Regression 1 0.00326 
Equal adjusted means 1 0.000712 0.0007 12 3.41 0. 092 
Error 1 1  0.00230 0.000209 
Source 
Overall regression 1 0.00326 
Equal regressions 2 0.000887 0.000443 2.09 0.174 
Equal adjusted 1 0.000712 
means 
Equal slopes 1 0.000175 0.000175 0.826 0.385 
Error (each regression) 10 0.00212 0.000212 
TOTAL 13 0.00626 
Between means 1 0.00149 
Covariates 1 0.00248 0.00248 11.9 0.006 
Error I I 0.00230 0.000209 
Degrees of 
freedom 
Note Plasma clearance = doselAUC - llsleep time; hence, sleep time - AUC 
*Coefficient = 0.0000471; SE = 0.0000137; t test value = 3.44; P = 0.006. 
B. Means and regression results 
Data Analysis System. All calculations were 
performed on an Amdahl 470lV8 computer of 
the Michigan Terminal System. 
Sum of 
squares 
Placebo-ketamine 
Results 
Diazepam-ketamine 
Ketamine exhibited triexponential decay un- 
der both test conditions (as confirmed by the F 
test). Fig. 1 shows ketamine concentrations for 
each condition in a representative subject and 
the corresponding fit to a three-term exponential 
equation. Table I lists the means and corre- 
sponding differences between plasma concen- 
trations of ketamine under each treatment con- 
dition. Diazepam pretreatment was associated 
with elevated ketamine levels 3, 4, 5, 10, 20 
min and 1 and 8 hr after dosing (P < 0.05; 
Mean 0.0723 0.0516 
Adjusted mean 0.0693 0.0546 
SE 0.00553 0.00553 
Intercept 0.323 0.0177 
N 7 7 
Constant 0.0225 0.0274 
Plasma clearance slope 0.0000588 0.0000336 
Regression SE 0.0143 0.0149 
RZ 0.671 0.346 
Significance 0.024 0.165 
two-way analysis of variance). When calculated 
according to the trapezoidal rule, the AUC from 
2 min to 8 hr exhibited corresponding differ- 
ences between the two treatments. AUC was 
elevated by diazepam pretreatment (P < 0.05). 
These differences correlated positively with dif- 
ferences in body weight (P < 0.05), but the 
time points were not associated with differences 
in levels of KI and KII (Tables I1 and 111). There 
were no significant differences in AUC of KI 
and KII from 2 to 30 min as well as from 2 to 
8 hr. 
Kinetics were calculated for each condition 
and are summarized in Table IV. Although 
there were no apparent differences in the first- 
order rate parameters, plasma clearance was 
P 
I 
Mean 
square F 
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* T n e  to follow a simple command (P  = 0.021). 
+Time to answer with simple sentences (P = 0.037). 
Table VI. Correlation of ketamine plasma fevels with duration of' anesthesia 
Table VII. Twentyfour-hour urinary 
excretion data (mg/24 hr) 
Subject 
No. 
Subject Placebo- Diazepam- 
No. ketamine ketcrmine 
Ketamine ( t  = 0.102; P > 0.30) 
1 9.71 
2 6.84 
3 2.37 
4 1.74 
5 2.50 
6 1.48 
7 5.86 
8 
- 
3.45 
X 4.24 
KI (t = 0.460; P > 0.30) 
I 2.92 
2 7.76 
3 2.39 
4 3.81 
5 3.38 
6 3.10 
7 4.03 
8 
- 7.07 
X 4.31 
KII (t = 0.526; P > 0.30) 
1 10.8 
2 38.9 
3 10.2 
4 28.0 
5 24.4 
6 11.0 
7 12.0 
8 
- 
30.8 
X 20.7 
I 73.2 17.0 907 17.0 907 
2 81.8 18.4 1200 18.4 1200 
3 70.0 20.5 1080 23.8 96 1 
5 68.0 12.2 1040 18.9 589 
6 69.2 17.0 1070 18.5 973 
7 59.9 9.5 1050 12.1 89 1 
- 
8 71.6 10.2 1240 10.2 1240 
X + SE 15.0 t 1.6 1080 2 40 17.0 t 1.8 966 + 82 
Weight 
(kg) 
*Estimated tiom mean o f  remaining seven values. 
decreased by diazepam from 848 to 719 mllkgl 
hr (P < 0.05; one-tailed t test). Comparison of 
these kinetic parameters with duration of anes- 
thesia revealed several interesting results. 
AUC, as calculated from the integrated triexpo- 
nential fit for each subject, correlated positively 
with duration of anesthesia, as measured by 
time until first ability to follow a simple com- 
mand as well as time to answer verbal com- 
mands with simple sentences (P < 0.05). Since 
plasma clearance is equal to doseIAUC, the in- 
verse of sleep time correlated with plasma 
clearance. One-way analysis of covariance in- 
dicated a positive linear relationship between 
inverse sleep time and plasma clearance for the 
overall condition as well as for placebo pre- 
treatment (P < 0.05; Table V). There was an 
additional trend that suggested another additive 
effect of diazepam on sleep time that was unre- 
lated to alterations in plasma clearance of 
ketamine itself (P = 0.046; one-tailed t test). 
These effects corresponded to a relative in- 
crease in duration of anesthesia (as measured by 
ability to follow simple commands) from 
15.0 k 1.6 min in the placebo condition to 
21.7 * 3.2 min with diazepam pretreatment. 
Fig. 2 illustrates this analysis and shows the 
relationship between plasma clearance and the 
inverse of sleep time for each subject under both 
treatment conditions. It should be noted that 
sleep time is proportional to AUC. Since 
AUC = doselplasma clearance, sleep time is 
Placebo-ketcrmine 
Duration 
No. I *  
(min) 
Plasma 
level 
( n g W  
Duration 
No. 2 f  
(min) 
Plasma 
level 
(nglml) 
Volume 36 
Number 5 
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proportional to I /plasma clearance and l/sleep 
time is proportional to clearance. We chose the 
latter plot for Fig. 2 because we believe that 
plasma clearance is a more physiologic measure 
than AUC. Fig. 2 can also be viewed as a plot 
of AUC against sleep time in which the greater 
the AUC, the longer the sleep time, which ob- 
viously makes good sense. After all, it is the 
drug in the body (as reflected by the AUC) that 
induces the "sleep" or anesthesia. 
Although there was no correlation between 
plasma concentrations and duration of anesthe- 
sia, the thresholds at which anesthesia occurred 
were remarkably close. Plasma concentrations 
(X ? SE) at which subjects were first able to 
follow commands were 1080 2 40 nglml after 
placebo and 1070 * 120 nglml after diazepam 
(Table VI). The time course of anesthesia, 
however, correlated more closely in most sub- 
jects with the time course of ketamine within 
the second compartment of the model. This is 
illustrated for subject No. 7 in Fig. 3. Peak 
levels of ketamine are attained approximately 2 
to 3 min after injection and fall exponentially in 
the ensuing period. After approximately 5 to 10 
min, the second compartment exhibits a parallel 
decline. Commonly described as at pseudo- 
equilibrium between these compartments, plas- 
ma levels would reflect those of the second 
compartment at the later time points. As can be 
seen in Fig. 3, compartment two shows slightly 
elevated levels under the diazepam-ketamine 
condition. This is consistent with the increases 
Duration 
No. I *  
(min) 
in mean plasma ketamine levels at some time 
points after diazepam. Additional information 
obtained from the time course of ketamine in 
the three-compartment model predicts that there 
would be no differences in elimination (percent 
dose) under the two conditions. This prediction 
was confirmed by actual urinary ketamine, KI, 
and KII data (Table VII). 
Twenty-four hours after each subject com- 
pleted both treatments (placebo-ketamine or 
diazepam-ketamine), he was asked to comment 
on the two sessions with respect to verbalization 
of each experience (first or second), recall of 
events, recall of emergence, and whether he 
would be willing to repeat each experience. 
These data were assigned to the appropriate 
treatment sequence when the study was com- 
pleted and data were summarized. When asked 
to describe the experience after what turned out 
to be diazepam-ketamine treatment, six of 
seven subjects felt it was pleasant or favorable 
and one of seven felt it was unfavorable. After 
the placebo-ketamine treatment, five of eight 
subjects felt it was unfavorable and three of 
eight felt it was favorable (P < 0.05; chi-square 
analysis). Five subjects said they would repeat 
the diazepam-ketamine anesthesia and two said 
they would not; four subjects said they would 
repeat the placebo-ketamine regimen, while 
three said they would not and one was unde- 
cided. After eliminating the one who was un- 
decided from analysis, chi-square analysis indi- 
cated a P value >0.05. 
Plasma 
level 
(nglml) 
Duration 
No. 2 f  
(min) 
Plasma 
level 
(nglml) 
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Discussion 
Our results with ketamine are in close agree- 
ment with previous reports and our own experi- 
ence with surgical volunteers.%etamine ki- 
netics appear to follow at least a three-term 
exponential decay, corresponding to a three- 
compartment model of plasma and tissue distri- 
bution. The time course of anesthesia follows 
that of the predicted second compartment more 
closely than that of the plasma compartment, as 
plasma levels fall rapidly in the first few min- 
utes after injection while anesthesia persists for 
a longer period. Duration of anesthesia was lin- 
early related to AUC and inversely related to 
clearance. Thus the longer the duration of anes- 
thesia, the larger the AUC. It should be noted 
that it is generally preferable to model the onset 
and offset of pharmacologic effects with a sepa- 
rate effect compartment rather than to assign the 
biophase to one of the compartments of the 
three-compartment model. It is likely that the 
locus of ketamine action does not correspond to 
any of the compartments used to model the ki- 
netics of its duration. 
Diazepam pretreatment raised plasma keta- 
mine levels slightly and decreased its rate of 
clearance. It prolonged sleep time in these sub- 
jects, which was most likely a result of two 
independent effects: the additive sedative effect 
of diazepam and the fact that diazepam de- 
creases ketamine clearance, thereby prolonging 
sleep time. While ketamine clearance from 
plasma partially determines the termination of 
its effects, redistribution from the brain is also 
important. Diazepam reduces the cardiac stimu- 
lant effect of ketamine, which provides a pos- 
sible explanation of the enhanced plasma levels 
and decreased clearance of ketamine after pre- 
treatment with d i a ~ e p a m . ~ ,  '3 16' 
There appeared to be little correlation be- 
tween duration of ketamine anesthesia and ap- 
pearance of KI and KII. The decline in plasma 
levels during anesthesia duration did not corre- 
late with the appearance of these substances. It 
is interesting that the total 24-hr urinary excre- 
tion of ketamine, KI, and KII (Table VI) ac- 
cou:lts for only about 20% of the total ketamine 
dose. Ketamine and its metabolites may be se- 
questered in body tissues such as fat, suggesting 
the existence of a depot compartment not de- 
tectable on the basis of the present 24-hr plasma 
data. It is also known that there are additional 
potential ketamine metabolites that were not 
identified by this assay. Obviously, more in- 
vestigations are required to determine whether 
ketamine anesthesia is terminated by redistribu- 
tion from the second compartment rather than 
by biotransformation. As a working hypothesis, 
however, redistribution of ketamine seems to be 
the more important variable. 
Diazepam pretreatment has been associated 
with a decrease in the frequency of emergence 
delirium from ketamine anesthesia? and we 
found it enhanced subject acceptance of keta- 
mine. There are several possibilities regarding 
this interaction. It has bken suggested that 
ketamine may be biotransformed to a psychoto- 
mimetic that induces this effect. Diazepam pre- 
treatment may thus reduce the formation of 
these substances. There is in vitro evidence that 
diazepam does reduce ketamine biotransforma- 
tion,' but we found no evidence for such an 
effect on ketamine metabolism. Alternative 
hypotheses are that diazepam may enhance 
y-aminobutyric acid-mediated transmission, 
which may be altered by ketamine, or that diaz- 
epam may simply reduce delirium by means of 
nonspecific sedative and/or amnestic proper- 
ties. In any case, our study provides evidence 
that diazepam pretreatment has significant ef- 
fects on ketamine anesthesia and kinetics. After 
diazepam, ketamine plasma levels are slightly 
enhanced, plasma ketamine clearance is slightly 
reduced, and ketamine anesthesia is more ac- 
ceptable. Our data also indicate that much more 
needs to be learned about this remarkable drug 
whose place in clinical anesthesia is still being 
debated. 
We are grateful to Drs. John G .  Wagner and Carl 
M. Metzler for the use of their computer programs 
CSTRIP and NONLIN, and to Mr. B. Mathews, 
Mrs. S. Tait, and S. Demetriou for analytic efforts. 
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